Visit KQAK 105.7
Visit The Peak 104.1
Visit 95.7 The Ranch
Visit 92.5 The Ticket
Visit KBNW 104.5AM AND 1340AM
Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by MeiraGTx

News headline image
MeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of Directors
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports Third Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports Second Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports First Quarter 2025 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson’s Disease and Industrialize MeiraGTx’s Proprietary Manufacturing Process
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Third Quarter 2024 Financial and Operational Results and Recent Business Updates
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Positive Data from Randomized, Sham-controlled Clinical Bridging Study of AAV-GAD for the Treatment of Parkinson’s Disease
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
News headline image
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
From MeiraGTx
Via GlobeNewswire
Tickers MGTX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.